Formulation and Evaluation of Olmesartan Mucoadhesive Buccal Patches

  • Unique Paper ID: 163369
  • Volume: 10
  • Issue: 11
  • PageNo: 2424-2433
  • Abstract:
  • The main objective of the present study was to improve bioavailability of Olmesartan and decrease the frequency of dosage form administration by sustained release formulation of the drug from the mucoadhesive drug delivery system. Olmesartan belongs to the drug class known as an angiotensin II receptor (type AT) antagonist, orally active and undergoes first-pass metabolism by cytochrome P450 enzymes. It has an extensive and highly variable hepatic first pass metabolism following oral administration having half life of 10-15hr.The usual dose of Olmesartan is 10-20 mg twice daily with systemic bioavailability of 40- 50% due to extensive “first-pass” metabolism and has a narrow absorption window. These characteristics make Olmesartan a suitable drug candidate for mucoadhesive drug delivery system. Olmesartan containing mucoadhesive buccal patches were prepared by solvent Casting evaporation method. The buccal patches were formulated using polymers HPMC K 100 and Carbopol 934 alone and in combination. FTIR analysis of drug and excipients binary mixtures showed no interactions. The buccal patches were evaluated for weight variation, thickness, folding endurance, content uniformity, swelling index, in-vitro diffusion study, in-vitro residence time and in-vitro Mucoadhesive strength. Among nine formulations using factorial approach F4 showed maximum release 94.21% upto 8hr . Mucoadhesive buccal films of Olmesartan were successfully prepared and offers a promising alternative to oral delivery.

Cite This Article

  • ISSN: 2349-6002
  • Volume: 10
  • Issue: 11
  • PageNo: 2424-2433

Formulation and Evaluation of Olmesartan Mucoadhesive Buccal Patches

Related Articles